The French biotech has presented positive Phase II data on lacutamab in mycosis fungoides at the EORTC-CLTG meeting in Madrid which looks to have de-risked the asset.

Innate’s lead candidate has reached the end of the road in head and neck carcinoma after a disappointing interim Phase III trial analysis but hope remains that a combination with partner AstraZeneca's Imfinzi could succeed elsewhere.

Adding oleclumab and monalizumab to the PD-L1 inhibitor improved PFS, while another study showed improved real-world outcomes.

Last year saw the number of applications accepted onto the European Medicines Agency’s priority medicines scheme inch up and the notoriously high rejection rate for applications drop.